Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor (pages 90–97)
Scott M. Schuetze, Vanessa Bolejack, Edwin Choy, Kristen N. Ganjoo, Arthur P. Staddon, Warren A. Chow, Hussein A. Tawbi, Brian L. Samuels, Shreyaskumar R. Patel, Margaret von Mehren, Gina D'Amato, Kirsten M. Leu, David M. Loeb, Charles A. Forscher, Mohammed M. Milhem, Daniel A. Rushing, David R. Lucas, Rashmi Chugh, Denise K. Reinke and Laurence H. Baker
Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30379
Dasatinib demonstrates no significant antisarcoma activity in patients with epithelioid sarcoma or solitary fibrous tumor. Patients with alveolar soft part sarcoma have prolonged disease progression–free and overall survival, but this is not necessarily caused by dasatinib. A small minority of patients with chondrosarcoma or chordoma experience an objective tumor response or prolonged stabilization of disease, and this suggests that dasatinib treatment should be further evaluated for these sarcoma subtypes. See also pages 20-4.